GeneDx Holdings (WGS) Misses Q1 EPS by 29c ; Offers Guidance

GeneDx Holdings (NASDAQ: WGS) reported Q1 EPS of ($0.23), $0.29 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $87.1 million versus the consensus estimate of $78 million.

GUIDANCE:

GeneDx Holdings sees FY2025 revenue of $360-375 million, versus the consensus of $358.6 million.

For earnings history and earnings-related data on GeneDx Holdings (WGS) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• Niagen Bioscience files to sell up to $50M in common stock
• Occidental Petroleum releases Q2 2026 earnings considerations